This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD.
The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.

开始日期2025-09-01

申办/合作机构

Canadian Institutes of Health Research

NCT07076823

/ Recruiting临床1期IIT

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer: a Phase I Trial

Colorectal cancer (CRC), ranking third in incidence among men and second in women globally with third-highest mortality in the US, remains a major health challenge despite multimodal therapies, particularly for advanced-stage patients with poor prognosis where immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 blockers have emerged as transformative agents by reinvigorating anti-tumor immunity through PD-1/PD-L1 pathway inhibition. While MSI-H CRC's high mutational burden renders it susceptible to immunotherapy, clinical trials demonstrate durable responses with domestic ICIs such as tislelizumab showing 41.2% ORR, 14.4-month PFS, and 28.7-month OS in metastatic MSI-H CRC, yet unmet needs persist. Intriguingly, SGLT-2 inhibitor exhibit promising oncolytic potential, particularly when combined with ICIs, as evidenced by observational studies revealing enhanced tumor control in pancreatic ductal adenocarcinoma through metabolic-immunologic crosstalk and our preclinical data showing synergistic CRC growth suppression with the SGLT-2 inhibitor canagliflozin plus PD-1 blockade. This phase II trial investigates the safety and efficacy of canagliflozin-tislelizumab combination in metastatic MSI-H CRC, evaluating its impact on PFS, OS, and ORR while dissecting tumor microenvironment modulation mechanisms, thereby pioneering a novel metabolic-immunotherapy paradigm that could redefine treatment paradigms through dual metabolic-immune regulation.

开始日期2025-07-31

申办/合作机构

四川大学华西医院（四川省国际医院）

CTIS2024-519109-36-00

/ Recruiting临床1期

- BLCL-CAN-EU-01

开始日期2025-07-09

申办/合作机构

Tecnimede Sociedade Tecnico Medicinal SA

100 项与卡格列净相关的临床结果

登录后查看更多信息

100 项与卡格列净相关的转化医学

登录后查看更多信息

100 项与卡格列净相关的专利（医药）

登录后查看更多信息

2,070

项与卡格列净相关的文献（医药）

2025-12-31·RENAL FAILURE

Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling

Article

作者: Ma, Sai ; Zhai, Jianlong ; Wang, Zhongli ; Zhang, Tingting ; Guo, Yifang ; Cao, Boce ; Zhang, Guorui ; Lu, Fan ; He, Lili ; Liang, Yi ; Wang, Qiuyan ; Zuo, Qingjuan

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) exhibit renoprotective effects in diabetic and nondiabetic patients; however, the underlying mechanism remains unclear. This study aimed to investigate the effects of canagliflozin (an SGLT2i) on salt-sensitive hypertensive kidneys. Male Dahl salt-sensitive rats were fed a high-salt (8%) diet and then orally administered canagliflozin 30 mg/kg/day or 0.5% hydroxypropyl methylcellulose solution for 12 weeks. Thus, a high-salt-induced model of hypertensive kidney injury with premature aging was established to evaluate the protective effects and related mechanisms of canagliflozin on hypertensive kidneys. Canagliflozin reduced blood pressure, the serum creatinine concentration, and urinary albumin excretion in high-salt rats. Hematoxylin and eosin, Masson, and senescence-associated β-galactosidase (staining were performed on rat kidneys, revealing that canagliflozin alleviated renal fibrosis and premature aging. Immunohistochemical analysis and protein detection demonstrated that canagliflozin increased the expression of silent information regulator 6 (SIRT6) in the kidney, inhibited the expression of the hypoxia-inducible factor-1 alpha (HIF-1α) protein and its target genes, and alleviated kidney damage and premature aging. In summary, canagliflozin ameliorates renal injury and premature aging in male Dahl salt-sensitive rats fed high salt with associated changes in SIRT6/HIF-1α signaling.

2025-12-01·Current Neurology and Neuroscience Reports

The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

Review

作者: Moustafa, Bayan ; Trifan, Gabriela

PURPOSE OF REVIEW:

Diabetes is a well-established risk factor for stroke. Understanding the pathophysiology of this connection is crucial to implementing appropriate prevention strategies. Lately, there has been a paradigm shift in the care of individuals with diabetes toward the use of glucose-lowering medications with potential cardiovascular, cerebrovascular or cardiorenal benefits. The aim of this article is to provide a critical analysis of the role of diabetes in cerebrovascular disease and current evidence and recommendations for the use of glucose-lowering medication with particular focus on the sodium glucose cotransporter-2 inhibitor (SGLT2i) class.

RECENT FINDINGS:

Intensive glycemic control in individuals with diabetes reduces the risk of microvascular complications, but there is less clear evidence for decreasing risk of macrovascular events (e.g., stroke). A multifaceted management of diabetes addressing healthy lifestyle practices, glycemic control, and optimization of other cardiovascular risk factors is highly recommended. SGLT2i are the latest class of antihyperglycemic agents available for diabetes management. Canagliflozin and empagliflozin are associated with reduction in major adverse cardiovascular events (MACE). Dapagliflozin did not reduce the rate of MACE but is associated with reduction in heart-failure related death and hospitalization and has the potential to decrease dementia risk. Ertugliflozin decreases rates of hospitalization related to heart failure however it was non-inferior to placebo in reducing MACE. There is increasing evidence that the use of SGLT2i may reduce the risk of stroke, particularly hemorrhagic stroke, in individuals with type 2 diabetes and a high risk of cardiovascular events, and that SGLT2i may also be beneficial for brain health by decreasing risk of cognitive decline and dementia. Antihyperglycemic therapy should be tailored to patients' circumstances. SGLT2i treatment should be considered in patients with type 2 diabetes and established or high-risk cardiovascular disease, heart failure, or chronic kidney disease, to reduce the overall cerebro-cardiovascular and renal risks.

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin

Review

作者: Dong, Weiyu ; Wang, Yanyan ; Fan, Shaohua

The use of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors, specifically canagliflozin and dapagliflozin, has expanded from diabetes treatment to promising anticancer applications. Epidemiological links between diabetes and certain cancers highlight the potential of these agents in oncology, as SGLT2 is highly expressed in various tumor types. By inhibiting glucose uptake, canagliflozin and dapagliflozin disrupt glycolysis-dependent tumor growth, promoting apoptosis and reducing proliferation across multiple cancer models, including liver, prostate, and lung cancers. Key pathways involved in these effects include PI3K/AKT, mTOR, and AMPK signaling. Importantly, the combination of SGLT2 inhibitors with chemotherapy or radiotherapy has been shown to enhance antitumor efficacy and reduce treatment resistance, underscoring their potential as adjunctive therapies. However, adverse effects, such as increased risk of infection, and the need for more comprehensive mechanistic studies limit current applications. Future research should focus on expanding the understanding of these mechanisms, evaluating efficacy in additional tumor types, and optimizing combination therapies to mitigate side effects. SGLT2 inhibitors thus represent a novel class of metabolic modulators with potential for significant impact in cancer therapeutics.

187

项与卡格列净相关的新闻（医药）

2025-09-17

·国际糖尿病idiabetes

EASD 2025 | 破局糖尿病心血管风险，药物与行为干预缺一不可

编者按在2025年第61届欧洲糖尿病研究协会（EASD）年会上，多项研究探讨了不同治疗策略和基线特征对2型糖尿病（T2D）患者心血管及肾脏结局的影响。从胰高血糖素样肽-1受体激动剂（GLP-1RA）、二十碳五烯酸乙酯（IPE），到基础胰岛素和生活方式干预，这些研究不仅深化了对现有疗法作用机制的理解，也为个体化治疗决策提供了新的循证依据。本文精选五项研究，旨在为临床实践带来启发。 01 Comparative cardiovascular effectiveness of GLP-1 RAs vs insulin in early-onset type 2 diabetes 一项基于瑞典全国登记数据的研究，比较了早期发病（诊断年龄<40岁）与晚期发病（≥40岁）T2D患者起始GLP-1 RA与胰岛素治疗对心血管疾病（CVD）风险的影响。研究采用逆概率加权法校正混杂因素，并进行意向性治疗分析。结果表明，在二甲双胍基础上，与胰岛素相比，GLP-1 RA在早期发病T2D患者中CVD的风险比（RR）为0.81（95%CI：0.63~1.00），而在晚期发病患者中为0.73（95%CI：0.69~0.76）。值得注意的是，GLP-1 RA在早期发病患者中的心血管保护作用主要体现在治疗开始后的前4年内，第1年、第4年和第10年的RR分别为0.57、0.77和0.84（图1）。在治疗第4年时，每1000例使用GLP-1 RA的患者比使用胰岛素患者减少12例CVD事件。研究提示，对于早期发病T2D患者，优先选择GLP-1 RA可显著降低早期心血管风险，其相对有效性与晚期发病患者相当。图1. 使用GLP-1RA和胰岛素T2D患者的CVD风险比 02 口服司美格鲁肽对不同基线HbA1c和BMI T2D患者心血管结局的影响：SOUL试验分析 Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial SOUL试验显示，每日一次口服司美格鲁肽14 mg可显著降低T2D患者14%的主要不良心血管事件（MACE）风险。本项事后分析旨在评估口服司美格鲁肽的心血管获益是否受基线糖化血红蛋白（HbA1c）和体重指数（BMI）的影响，共纳入9650例合并动脉粥样硬化性心血管疾病（ASCVD）或慢性肾脏病（CKD）的T2D患者，平均随访47.5个月。结果显示，口服司美格鲁肽的心血管获益在不同BMI分组中保持一致，无论按BMI 30 kg/m2或平均体重87.9 kg分组，均未观察到显著差异。然而，其心血管获益程度与基线HbA1c水平相关：在HbA1c>8.0%的患者中效果更为显著；进一步分层分析显示，HbA1c>7%的患者MACE风险均可降低（图2）。研究提示，在合并ASCVD和/或CKD的T2D患者中，基线血糖水平较高者可能从口服司美格鲁肽中获得更明显的心血管获益。图2. 不同HbA1c、BMI和体重亚组的心血管获益 03 IPE在不同基线甘油三酯-葡萄糖指数患者中的疗效分析 Efficacy of icosapent ethyl across the spectrum of baseline triglyceride glucose indices REDUCE-IT试验的事后分析评估了二十碳五烯酸乙酯（IPE）在不同基线甘油三酯-葡萄糖（TyG）指数患者中的心血管疗效。TyG指数作为胰岛素抵抗的替代指标，其水平越高，主要终点事件（心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定性心绞痛）发生率也越高。分析显示，无论患者基线TyG指数处于低、中或高三分位，IPE均能显著降低主要终点事件风险，各组的HR分别为0.81、0.70和0.74（交互P=0.49），显示出一致的疗效。在二级预防亚组中也观察到类似结果（图3）。治疗1年后，TyG指数的下降幅度与总体人群的心血管获益无显著关联，但在二级预防亚组中，TyG指数降幅越大，治疗获益越明显。研究表明，在已接受他汀治疗且低密度脂蛋白胆固醇（LDL-C）控制良好，但存在轻中度高甘油三酯血症的CVD或糖尿病高危患者中，更高基线TyG指数提示更高的心血管残余风险，而IPE可有效降低这一风险，且疗效不受基线TyG水平影响。图3. 不同基线TyG指数时IPE的疗效 04 基础胰岛素治疗对T2D患者心肾结局的影响：CANVAS和CREDENCE试验合并分析 Impact of background insulin treatment on cardiorenal outcomes in patients with type 2 diabetes: a patient-level analysis of merged CANVAS and CREDENCE trials 通过对CANVAS和CREDENCE两项大型试验数据的合并分析，研究评估了基础胰岛素和二甲双胍单药治疗对高心血管风险T2D患者心肾结局的影响，并探索了钠-葡萄糖共转运蛋白2（SGLT2）抑制剂卡格列净的作用。结果显示，接受胰岛素单药治疗的患者年龄较大、糖尿病病程较长、血糖控制较差。经多变量校正后，胰岛素单药治疗与心力衰竭住院或心血管死亡（HR=1.18）和MACE（HR=1.22）风险升高相关。相比之下，二甲双胍单药治疗虽在未校正模型中显示保护趋势，但在充分调整后其关联不再显著。卡格列净治疗可显著降低胰岛素单药治疗患者的心力衰竭住院或心血管死亡和MACE风险，提示SGLT2抑制剂在胰岛素治疗背景下具有心肾保护作用。 05 自我报告的体力活动水平与新诊断T2D患者心血管事件和全因死亡的相关性 Association between self-reported physical activity and cardiovascular events and all-cause mortality in individuals recently diagnosed with type 2 diabetes 一项基于丹麦DD2队列的前瞻性研究探讨了自我报告的体力活动水平对新诊断无既往CVD的T2D患者预后的影响。根据Saltin-Grimby体力活动等级量表，18%的参与者为久坐，62.5%为轻度活动，19.5%为中高强度体力活动（MVPA）。中位随访8.4年期间，体力活动水平与MACE和全因死亡风险呈剂量依赖负相关。与久坐者相比，轻度和MVPA参与者的MACE风险分别降低21%和29%，全因死亡风险分别降低27%和35%（图4）。进一步校正LDL-C、HbA1c、收缩压、估算肾小球滤过率（eGFR）和尿白蛋白/肌酐比值（UACR）等传统心血管危险因素后，MVPA仍与MACE（HR=0.68）和全因死亡（HR=0.67）风险显著降低相关，而轻度活动的保护作用则不再显著。该研究证实，自我报告的MVPA是新诊断T2D患者心血管和死亡风险的独立预测指标，强调了早期生活方式干预的重要性。图4. 自我报告的体力活动水平与MACE和全因死亡的关系参考文献： [1] Y. Wei, et al. Comparative cardiovascular effectiveness of GLP-1 RAs vs insulin in early-onset type 2 diabetes. Diabetologia, 2025; 68 (Suppl 1):S1–S754. [2] S.E. Inzucchi, et al. Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial. Diabetologia, 2025; 68 (Suppl 1):S1–S754. [3] R. Aggarwal, et al. Efficacy of icosapent ethyl across the spectrum of baseline triglyceride glucose indices. Diabetologia, 2025; 68 (Suppl 1):S1–S754. [4] M. Chiriacò, et al. Impact of background insulin treatment on cardiorenal outcomes in patients with type 2 diabetes: a patient-level analysis of merged CANVAS and CREDENCE trials. Diabetologia, 2025; 68 (Suppl 1):S1–S754. [5] L.B. Eriksen, et al. Association between self-reported physical activity and cardiovascular events and all-cause mortality in individuals recently diagnosed with type 2 diabetes. Diabetologia, 2025; 68 (Suppl 1):S1–S754. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）

临床结果

2025-09-15

·国家药品监督管理局

2025年09月15日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CXHS2400097、CXHB2500087安瑞克芬注射液海思科医药集团股份有限公司国药准字H202500142025年09月09日2CXHS2500005枸橼酸伏维西利胶囊锦州奥鸿药业有限责任公司国药准字H202500232025年09月09日3CXHS2500006枸橼酸伏维西利胶囊锦州奥鸿药业有限责任公司国药准字H202500242025年09月09日4CXSS2400041Sabin株脊髓灰质炎灭活疫苗（Vero细胞）北京民海生物科技有限公司国药准字S202500512025年09月09日5CXZS2400036枇杷清肺饮颗粒河北万岁药业有限公司国药准字C202500112025年09月09日6CYHB2402063恩格列净片山东新时代药业有限公司国药准字H202581972025年09月12日7CYHB2450141注射用头孢他啶重庆吉斯瑞制药有限责任公司国药准字H202581962025年09月12日8CYHB2450142注射用头孢他啶重庆吉斯瑞制药有限责任公司国药准字H202581952025年09月12日9CYHB2450547头孢泊肟酯片浙江普洛巨泰药业有限公司————2025年09月12日10CYHB2501287甲苯磺酸艾多沙班片辰欣药业股份有限公司————2025年09月12日11CYHB2501324盐酸多巴酚丁胺注射液浙江沣华医药科技有限公司————2025年09月12日12CYHS2202121国、CYHB2500713水合氯醛灌肠剂海南天盛保和生物科技有限公司国药准字H202553872025年09月09日13CYHS2202122国、CYHB2501017水合氯醛灌肠剂海南天盛保和生物科技有限公司国药准字H202553882025年09月09日14CYHS2300221马来酸奈拉替尼片湖南科伦制药有限公司国药准字H202553372025年09月09日15CYHS2300737托拉塞米注射液江苏睿实生物科技有限公司国药准字H202554262025年09月09日16CYHS2300738托拉塞米注射液江苏睿实生物科技有限公司国药准字H202554272025年09月09日17CYHS2301749盐酸多巴胺注射液酒泉大得利制药股份有限公司国药准字H202554542025年09月09日18CYHS2302225西格列汀二甲双胍缓释片越洋医药开发（广州）有限公司国药准字H202554282025年09月09日19CYHS2302380波生坦片北京颐康兴医药有限公司国药准字H202553892025年09月09日20CYHS2302851盐酸甲氧氯普胺注射液四川邈济生物医药科技有限公司国药准字H202553712025年09月09日21CYHS2302985碳酸氢钠注射液江西璟瑞药业有限公司国药准字H202553902025年09月09日22CYHS2303053磷酸奥司他韦干混悬剂海南葫芦娃药业集团股份有限公司国药准字H202554552025年09月09日23CYHS2303085吡格列酮二甲双胍片（15mg/500mg）江苏安必生制药有限公司国药准字H202553572025年09月09日24CYHS2303124注射用头孢哌酮钠舒巴坦钠广东粤和泽药物研究有限公司国药准字H202553972025年09月09日25CYHS2303125注射用头孢哌酮钠舒巴坦钠广东粤和泽药物研究有限公司国药准字H202553982025年09月09日26CYHS2303156、CYHB2500607盐酸甲氧氯普胺注射液朗天药业（湖北）有限公司国药准字H202553992025年09月09日27CYHS2303337盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553912025年09月09日28CYHS2303338盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553922025年09月09日29CYHS2303339盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553932025年09月09日30CYHS2303407米诺地尔搽剂辽宁新高制药有限公司国药准字H202553382025年09月09日31CYHS2303409坎地沙坦酯氢氯噻嗪片（Ⅱ）浙江华海药业股份有限公司国药准字H202554562025年09月09日32CYHS2303497复方匹可硫酸钠颗粒北京民康百草医药科技有限公司国药准字H202554572025年09月09日33CYHS2303549乳果糖口服溶液国药控股星鲨制药（厦门）有限公司国药准字H202553722025年09月09日34CYHS2303550乳果糖口服溶液国药控股星鲨制药（厦门）有限公司国药准字H202553732025年09月09日35CYHS2303575酮咯酸氨丁三醇注射液重庆莱美药业股份有限公司国药准字H202553582025年09月09日36CYHS2303585甲磺酸伊马替尼片浙江麒正药业有限公司国药准字H202553392025年09月09日37CYHS2303589氯化钾注射液江西博泰药业有限公司国药准字H202554582025年09月09日38CYHS2303590氯化钾注射液江西博泰药业有限公司国药准字H202554592025年09月09日39CYHS2303625碘佛醇注射液重庆圣华曦药业股份有限公司国药准字H202554602025年09月09日40CYHS2400026氟比洛芬酯注射液宜昌人福药业有限责任公司国药准字H202554002025年09月09日41CYHS2400047乳果糖口服溶液广西维威制药有限公司国药准字H202554292025年09月09日42CYHS2400048乳果糖口服溶液广西维威制药有限公司国药准字H202554302025年09月09日43CYHS2400051盐酸甲氧氯普胺注射液中润药业有限公司国药准字H202554012025年09月09日44CYHS2400147法莫替丁注射液锦州奥鸿药业有限责任公司国药准字H202553402025年09月09日45CYHS2400262糠酸莫米松乳膏重庆华邦制药有限公司国药准字H202553592025年09月09日46CYHS2400263糠酸莫米松乳膏重庆华邦制药有限公司国药准字H202553602025年09月09日47CYHS2400267利多卡因凝胶贴膏陕西东科制药有限责任公司国药准字H202553412025年09月09日48CYHS2400280盐酸美金刚口服溶液沈阳天邦药业有限公司国药准字H202554022025年09月09日49CYHS2400306硫代硫酸钠注射液南京海辰药业股份有限公司国药准字H202554032025年09月09日50CYHS2400322注射用醋酸地加瑞克正大天晴药业集团股份有限公司国药准字H202553422025年09月09日51CYHS2400323注射用醋酸地加瑞克正大天晴药业集团股份有限公司国药准字H202553432025年09月09日52CYHS2400333盐酸戊乙奎醚注射液国药集团工业有限公司廊坊分公司国药准字H202553612025年09月09日53CYHS2400384熊去氧胆酸胶囊山东淄博新达制药有限公司国药准字H202553442025年09月09日54CYHS2400427他达拉非片山东汇泽生物制药有限公司国药准字H202553742025年09月09日55CYHS2400478氨氯地平贝那普利胶囊东阳祥昇医药科技有限公司国药准字H202553752025年09月09日56CYHS2400491甲氨蝶呤注射液吉斯美（武汉）制药有限公司国药准字H202554312025年09月09日57CYHS2400492甲氨蝶呤注射液吉斯美（武汉）制药有限公司国药准字H202554322025年09月09日58CYHS2400531夫西地酸乳膏湖北成田药业有限公司国药准字H202553622025年09月09日59CYHS2400552二甲双胍恩格列净片（Ⅰ）山东新时代药业有限公司国药准字H202554042025年09月09日60CYHS2400553二甲双胍恩格列净片（Ⅵ）山东新时代药业有限公司国药准字H202554052025年09月09日61CYHS2400556盐酸普罗帕酮注射液成都瑞尔医药科技有限公司国药准字H202554612025年09月09日62CYHS2400557注射用盐酸罗沙替丁醋酸酯浙江华海药业股份有限公司国药准字H202554062025年09月09日63CYHS2400625盐酸克林霉素棕榈酸酯颗粒广州一品红制药有限公司国药准字H202553762025年09月09日64CYHS2400628吡仑帕奈口服混悬液锦州奥鸿药业有限责任公司国药准字H202553942025年09月09日65CYHS2400638碘佛醇注射液重庆煜洋药业有限公司国药准字H202554332025年09月09日66CYHS2400662盐酸奥洛他定颗粒成都倍特药业股份有限公司国药准字H202554622025年09月09日67CYHS2400684马来酸氯苯那敏注射液辽宁海神联盛制药有限公司国药准字H202554452025年09月09日68CYHS2400704盐酸鲁拉西酮片山东新时代药业有限公司国药准字H202553452025年09月09日69CYHS2400712己酮可可碱缓释片普济生物科技（台州）有限公司国药准字H202553772025年09月09日70CYHS2400730、CYHB2501194托吡酯口服溶液梦阳药业（上海）有限公司国药准字H202553782025年09月09日71CYHS2400826富马酸伏诺拉生片重庆圣华曦药业股份有限公司国药准字H202554072025年09月09日72CYHS2400856吡仑帕奈片锦州奥鸿药业有限责任公司国药准字H202553632025年09月09日73CYHS2400857吡仑帕奈片锦州奥鸿药业有限责任公司国药准字H202553642025年09月09日74CYHS2400877盐酸贝尼地平片辰欣药业吉林有限公司国药准字H202554342025年09月09日75CYHS2400881替米沙坦氨氯地平片（II）成都奥邦药业有限公司国药准字H202553652025年09月09日76CYHS2400882替米沙坦氨氯地平片成都奥邦药业有限公司国药准字H202553792025年09月09日77CYHS2400893吗啉硝唑氯化钠注射液石家庄四药有限公司国药准字H202554462025年09月09日78CYHS2400906氨磺必利口服溶液仁合益康集团有限公司国药准字H202554632025年09月09日79CYHS2400914克立硼罗软膏浙江赛默制药有限公司国药准字H202553802025年09月09日80CYHS2400916法莫替丁注射液武汉福星生物药业有限公司国药准字H202553462025年09月09日81CYHS2400918琥珀酸普芦卡必利片漯河市汇创医药有限公司国药准字H202554472025年09月09日82CYHS2400934替格瑞洛片安若维他药业泰州有限公司国药准字H202554352025年09月09日83CYHS2400935替格瑞洛片安若维他药业泰州有限公司国药准字H202554362025年09月09日84CYHS2400940重酒石酸去甲肾上腺素注射液海南美康达药业有限公司国药准字H202553812025年09月09日85CYHS2400980己酮可可碱缓释片广东君康药业有限公司国药准字H202553472025年09月09日86CYHS2400995吡格列酮二甲双胍片（15mg/850mg）北京福元医药股份有限公司国药准字H202553662025年09月09日87CYHS2401007、CYHB2500786二甲双胍恩格列净片（Ⅰ）河南福森药业有限公司国药准字H202554082025年09月09日88CYHS2401048米拉贝隆缓释片南京易亨制药有限公司国药准字H202554642025年09月09日89CYHS2401087左氧氟沙星注射液陕西博森生物制药股份集团有限公司国药准字H202554092025年09月09日90CYHS2401106西咪替丁注射液石家庄迪斯凯威医药科技有限公司国药准字H202554102025年09月09日91CYHS2401133丙酸氟替卡松吸入粉雾剂润生药业有限公司国药准字H202554652025年09月09日92CYHS2401148沙库巴曲缬沙坦钠片迪沙药业集团有限公司国药准字H202553482025年09月09日93CYHS2401206盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司国药准字H202553492025年09月09日94CYHS2401208盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司国药准字H202553502025年09月09日95CYHS2401236卡格列净片沐邦（北京）医药科技有限公司国药准字H202553512025年09月09日96CYHS2401256盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554112025年09月09日97CYHS2401257盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554122025年09月09日98CYHS2401258盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554132025年09月09日99CYHS2401265乳果糖口服溶液江西远超医药科技有限公司国药准字H202553822025年09月09日100CYHS2401266乳果糖口服溶液江西远超医药科技有限公司国药准字H202553832025年09月09日101CYHS2401270磷酸奥司他韦胶囊山东鲁抗三叶制药有限公司国药准字H202554142025年09月09日102CYHS2401277注射用头孢他啶阿维巴坦钠安徽威尔曼制药有限公司国药准字H202554482025年09月09日103CYHS2401280枸橼酸西地那非口崩片山东新华制药股份有限公司国药准字H202553522025年09月09日104CYHS2401288他达拉非片辽宁鑫善源药业有限公司国药准字H202554152025年09月09日105CYHS2401289他达拉非片辽宁鑫善源药业有限公司国药准字H202554162025年09月09日106CYHS2401290他达拉非片辽宁鑫善源药业有限公司国药准字H202554172025年09月09日107CYHS2401294马来酸氟伏沙明片石家庄龙泽制药股份有限公司国药准字H202554662025年09月09日108CYHS2401297布南色林片山东京卫制药有限公司国药准字H202554672025年09月09日109CYHS2401306枸橼酸托瑞米芬片重庆圣华曦药业股份有限公司国药准字H202554182025年09月09日110CYHS2401311普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553672025年09月09日111CYHS2401312普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553682025年09月09日112CYHS2401314普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553692025年09月09日113CYHS2401319盐酸利多卡因注射液南京泽恒医药技术开发有限公司国药准字H202554682025年09月09日114CYHS2401323培哚普利氨氯地平片（Ⅰ）江西施美药业股份有限公司国药准字H202554192025年09月09日115CYHS2401324培哚普利氨氯地平片（Ⅲ）江西施美药业股份有限公司国药准字H202554202025年09月09日116CYHS2401325培哚普利氨氯地平片（Ⅱ）江西施美药业股份有限公司国药准字H202554212025年09月09日117CYHS2401401双醋瑞因胶囊赛灵药业科技集团股份有限公司国药准字H202553952025年09月09日118CYHS2401426盐酸贝尼地平片深圳大佛药业股份有限公司国药准字H202554372025年09月09日119CYHS2401427盐酸贝尼地平片深圳大佛药业股份有限公司国药准字H202554382025年09月09日120CYHS2401441法莫替丁注射液成都倍特药业股份有限公司国药准字H202553532025年09月09日121CYHS2401442二甲双胍恩格列净片（Ⅴ）北京双鹭药业股份有限公司国药准字H202554492025年09月09日122CYHS2401443二甲双胍恩格列净片（Ⅰ）北京双鹭药业股份有限公司国药准字H202554502025年09月09日123CYHS2401452盐酸去氧肾上腺素注射液云南龙海天然植物药业有限公司国药准字H202554692025年09月09日124CYHS2401493葡萄糖酸钙氯化钠注射液石家庄四药有限公司国药准字H202553962025年09月09日125CYHS2401546拉莫三嗪分散片仁合益康集团有限公司国药准字H202553542025年09月09日126CYHS2401548左炔诺孕酮片武汉九珑人福药业有限责任公司国药准字H202554222025年09月09日127CYHS2401581注射用阿糖胞苷石家庄迪斯凯威医药科技有限公司国药准字H202554392025年09月09日128CYHS2401622塞来昔布胶囊大桐制药（中国）有限责任公司国药准字H202554512025年09月09日129CYHS2401678巴瑞替尼片杭州民生药业股份有限公司国药准字H202554702025年09月09日130CYHS2401714尼可地尔片重庆莱美药业股份有限公司国药准字H202554522025年09月09日131CYHS2401734注射用硫酸艾沙康唑合肥亿帆生物制药有限公司国药准字H202554402025年09月09日132CYHS2401737甲硝唑凝胶合肥启旸生物医药科技有限公司国药准字H202554412025年09月09日133CYHS2401753盐酸丙卡特罗吸入溶液北京海步医药科技有限公司国药准字H202554232025年09月09日134CYHS2401803卡铂注射液中寰医药有限公司国药准字H202553552025年09月09日135CYHS2401839注射用亚胺培南西司他丁钠深圳华药南方制药有限公司国药准字H202553702025年09月09日136CYHS2401939硫酸艾沙康唑胶囊杭州沐源生物医药科技有限公司国药准字H202554532025年09月09日137CYHS2401960盐酸戊乙奎醚注射液广州瑞尔医药科技有限公司国药准字H202553842025年09月09日138CYHS2401961磷/碳酸氢钠血滤置换液山东齐都药业有限公司国药准字H202553852025年09月09日139CYHS2402067盐酸阿罗洛尔片成都苑东生物制药股份有限公司国药准字H202554242025年09月09日140CYHS2402128恩格列净片康臣药业（内蒙古）有限责任公司国药准字H202553562025年09月09日141CYHS2402307替格瑞洛片浙江京新药业股份有限公司国药准字H202554422025年09月09日142CYHS2402308替格瑞洛片浙江京新药业股份有限公司国药准字H202554432025年09月09日143CYHS2402345普拉洛芬滴眼液鲁南贝特制药有限公司国药准字H202554442025年09月09日144CYHS2403653地夸磷索钠滴眼液武汉先路医药科技股份有限公司国药准字H202554252025年09月09日145CYHS2403793布比卡因脂质体注射液湖南科伦制药有限公司国药准字H202446862025年09月09日146CYHS2403794布比卡因脂质体注射液湖南科伦制药有限公司国药准字H202446852025年09月09日147CYHS2403864氧江苏宝祥气体有限公司国药准字H202553862025年09月09日148CYZB2501317脉络通葵花药业集团（佳木斯）有限公司————2025年09月12日149CYZB2501818跌打活血胶囊江西远超医药科技有限公司————2025年09月12日150CYZB2501820牛黄清心丸(局方)河南乐同堂医药科技有限公司————2025年09月12日151CYZB2501821胃灵颗粒蓝耘智合生物科技有限责任公司————2025年09月12日152CYZB2501826乌鸡白凤丸广生堂药业（漳州）有限公司————2025年09月12日153CYZB2501829三七丹参颗粒海南鑫康达医药科技有限公司————2025年09月12日154JTH2500135注射用醋酸亮丙瑞林微球上海安必生制药技术有限公司————2025年09月12日155JTS2500071乙型肝炎疫苗-成品-标准品葛兰素史克（中国）投资有限公司————2025年09月12日156JTS2500072乙型肝炎疫苗-成品-内控品葛兰素史克（中国）投资有限公司————2025年09月12日157JXHS2400017、JXHB2500059雌二醇透皮喷雾剂吉瑞医药（中国）有限公司国药准字HJ202501092025年09月09日158JXHS2400053盐酸伊普可泮胶囊北京诺华制药有限公司国药准字HJ202400162025年09月09日159JXHS2400113盐酸卡马替尼片北京诺华制药有限公司国药准字HJ202400412025年09月09日160JXHS2400114盐酸卡马替尼片北京诺华制药有限公司国药准字HJ202400422025年09月09日161JYHB2400457厄多司坦胶囊辉盈（上海）医药科技有限公司————2025年09月12日162JYHB2500331恩扎卢胺软胶囊安斯泰来制药（中国）有限公司————2025年09月12日163JYHS2300113尼洛替尼胶囊瑞迪博士（北京）药业有限公司国药准字HJ202501102025年09月09日164JYHS2300114尼洛替尼胶囊瑞迪博士（北京）药业有限公司国药准字HJ202501112025年09月09日

疫苗申请上市高管变更

2025-08-29

·EINPresswire

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

100 项与卡格列净相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09592	卡格列净	A10BK02	DB08907

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病肾脏病	日本	Mitsubishi Tanabe Pharma Corp.	2022-06-20
糖尿病肾病	美国	Janssen Pharmaceuticals, Inc.	2019-09-27
2型糖尿病	美国	Janssen Pharmaceuticals, Inc.	2013-03-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏衰竭	临床3期	美国	Janssen Research & Development LLC	2020-03-10
射血分数保留型心力衰竭	临床3期	美国	Janssen Research & Development LLC	2020-03-10
射血分数降低的心力衰竭	临床3期	美国	Janssen Research & Development LLC	2020-03-10
心血管疾病	临床3期	美国	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	阿根廷	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	澳大利亚	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	比利时	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	加拿大	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	哥伦比亚	Janssen Research & Development LLC	2009-12-09
心血管疾病	临床3期	捷克	Janssen Research & Development LLC	2009-12-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02065791 (CANVAS, Pubmed \| Clin J Am Soc Nephrol)	临床3期	慢性肾病	4,401	Canagliflozin	積蓋繭衊鹽築繭構淵顧(積鑰網鏇艱選鏇糧醖顧): HR = 0.88 (95.0% CI, 0.8 ~ 0.98), P-Value = 0.02 更多	积极	2025-09-01
				Placebo
NCT01032629 (CANVAS, Pubmed \| Eur J Heart Fail)	临床3期	-	5,281	Canagliflozin	膚顧鏇遞選繭願蓋願鹹(築範廠製窪鏇積膚夢憲): HR = 0.65 (95.0% CI, 0.53 ~ 0.79) 更多	积极	2025-07-21
				Placebo
NCT03170518 (CTgov)	临床3期	2型糖尿病	171	placebo+canagliflozin (Placebo)	遞範願蓋窪壓壓鹹鹽繭(糧網餘醖願艱鏇夢壓繭) = 鏇顧築顧選願鏇製壓憲觸醖範蓋選醖遞鏇鏇鏇 (範觸鹹衊願鹽鹽蓋淵鏇, 0.191) 更多	-	2025-03-12
				Canagliflozin (Canagliflozin 100/300 mg)	遞範願蓋窪壓壓鹹鹽繭(糧網餘醖願艱鏇夢壓繭) = 獵憲築範顧壓淵鹹積簾觸醖範蓋選醖遞鏇鏇鏇 (範觸鹹衊願鹽鹽蓋淵鏇, 0.194) 更多
NCT03436693 (CTgov)	临床3期	糖尿病肾病	308	Canagliflozin (Canagliflozin 100mg)	鹹襯膚鹹夢淵鑰鹹選獵 = 醖鬱襯夢鏇繭網廠範製膚窪積選網醖餘鬱獵襯 (憲夢廠壓觸廠觸衊餘鑰, 觸製顧鬱積齋遞餘艱鏇 ~ 範醖淵廠鑰衊廠遞鏇範) 更多	-	2024-07-15
				Placebo (Placebo)	鹹襯膚鹹夢淵鑰鹹選獵 = 齋願獵鑰觸鏇構憲遞鑰膚窪積選網醖餘鬱獵襯 (憲夢廠壓觸廠觸衊餘鑰, 鑰餘壓蓋簾製襯鹽鹹願 ~ 積鏇範製糧繭憲鑰構膚) 更多
ADA2024	N/A	2型糖尿病	-	Canagliflozin 100 mg/d	鹹鑰廠夢淵鬱糧鬱襯鬱(鬱醖艱窪廠壓齋憲糧壓) = 膚遞鹽繭鹽餘衊願構襯糧構窪觸範鹹衊鏇餘觸 (獵淵選夢範憲窪觸艱觸 ) 更多	-	2024-06-14
1340-P (ADA2024)	N/A	糖尿病	-	SGLT2i	鏇鏇網衊築積膚獵鹹廠(衊積壓餘夢蓋壓積醖憲) = 觸鏇襯襯鹹選觸繭顧窪壓襯選夢顧淵鹽獵鹽淵 (蓋選遞艱願淵壓獵衊範, 16.6 ~ 19.7)	积极	2024-06-14
				DPP4i	鏇鏇網衊築積膚獵鹹廠(衊積壓餘夢蓋壓積醖憲) = 選壓構簾齋鬱壓簾鹽築壓襯選夢顧淵鹽獵鹽淵 (蓋選遞艱願淵壓獵衊範, 19.1 ~ 21.4)
NCT02065791 \| NCT01989754 \| NCT01032629 (CANVAS Program and CREDENCE trial, Pubmed \| Diabetes Obes Metab)	N/A	2型糖尿病	-	Canagliflozin	顧醖廠積鑰鬱鹹顧簾淵(鹽鹽衊餘築糧鑰選淵夢): HR = 0.83 (95% CI, 0.75 ~ 0.93) 更多	积极	2023-12-01
				Placebo
NCT02065791 (CREDENCE, Pubmed \| Circulation)	临床3期	糖尿病肾病	2,627	Canagliflozin	淵構觸餘選壓繭積繭鬱(選鬱構繭夢艱積醖簾蓋) = 齋憲艱淵壓壓齋壓願遞觸鬱鏇顧襯獵蓋蓋顧醖 (蓋製願壓壓廠簾簾構鹽 ) 更多	-	2023-08-22
NCT02065791 \| NCT01989754 \| NCT01032629 (CANVAS and CREDENCE Trials, Pubmed)	N/A	2型糖尿病 \| 心血管疾病 \| 糖尿病肾病 ... 更多	-	Canagliflozin	鏇觸夢醖簾醖廠鬱選顧(廠鬱鑰鑰構選廠夢簾糧) = 築餘窪襯網願膚壓醖壓膚積憲夢窪醖齋鏇淵築 (繭觸願糧範觸簾鹽醖鬱 )	-	2023-06-22